TherapeuticsMD, Inc. (NASDAQ:TXMD) has earned an average recommendation of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $15.71.
A number of equities analysts have weighed in on the company. Cowen and Company reissued an “outperform” rating and issued a $16.00 target price (up previously from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Oppenheimer Holdings, Inc. set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Monday, October 16th. Jefferies Group LLC reissued a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a research report on Tuesday, September 26th. Deutsche Bank AG reissued a “buy” rating and issued a $10.00 target price on shares of TherapeuticsMD in a research report on Wednesday, September 13th. Finally, Morgan Stanley assumed coverage on TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price for the company.
ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD, Inc. (TXMD) Given Average Rating of “Buy” by Analysts” was posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/13/therapeuticsmd-inc-txmd-given-average-rating-of-buy-by-analysts.html.
TherapeuticsMD (TXMD) opened at $5.67 on Monday. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same quarter in the previous year, the firm earned ($0.13) EPS. TherapeuticsMD’s revenue was down 19.7% on a year-over-year basis. equities research analysts predict that TherapeuticsMD will post -0.38 EPS for the current fiscal year.
In other news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was acquired at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $21,294.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 23.92% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in TXMD. Teachers Advisors LLC grew its stake in shares of TherapeuticsMD by 1.4% during the 1st quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock valued at $4,605,000 after purchasing an additional 9,077 shares during the period. Vanguard Group Inc. grew its stake in shares of TherapeuticsMD by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock valued at $70,574,000 after purchasing an additional 515,992 shares during the period. Geode Capital Management LLC grew its stake in shares of TherapeuticsMD by 10.1% during the 1st quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock valued at $9,213,000 after purchasing an additional 117,660 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of TherapeuticsMD by 10.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock valued at $4,510,000 after purchasing an additional 60,229 shares during the period. Finally, State Street Corp grew its stake in shares of TherapeuticsMD by 6.9% during the 1st quarter. State Street Corp now owns 3,903,491 shares of the company’s stock valued at $28,105,000 after purchasing an additional 253,237 shares during the period. Institutional investors and hedge funds own 71.40% of the company’s stock.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.